Program
CT-P43
Its studies are mostly in Psoriasis, led by Celltrion.
Furthest: phase 3, since Dec 13, 20203 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Celltrion | 30 open or running | phase 3since Dec 13, 2020 | Jun 8, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 8, 2020First study: phase 1 study in Healthy SubjectsFirst studyNCT04428814 · 271 enrolled · New Zealand
- Dec 13, 2020Phase 3 study in PsoriasisNCT04673786 · 509 enrolled · Estonia
- Apr 23, 2025Phase 1 study in Healthy Male SubjectsNCT06951828 · 162 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06951828Healthy Male Subjects · South Korea | 1 | Completed | Nov 26, 2025 | 162 |
| NCT04673786Psoriasis · Estonia | 3 | Completed | Aug 4, 2021 | 509 |
| NCT04428814Healthy Subjects · New Zealand | 1 | Completed | Feb 24, 2021 | 271 |
How it is read
Names in the registry
- “CT-P43”, 4 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.